Intellia Therapeutics 주식 (NASDAQ: NTLA)

Intellia Therapeutics (NASDAQ:NTLA) 주식

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

Equities

News

Markets

ETFs

ARKF

ARKG

ARKK

ARKW

CDNA

GTLB

IBTA

NTLA

PATH

PRME

RBLX

RPTX

2025년 3월 14일 금요일, 캐시 우드가 이끄는 아크 인베스트가 깃랩(NASDAQ:GTLB), 인텔리아 테라퓨틱스(NGM:NTLA), 프라임 메디슨(NGM:PRME), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 로블록스(NYSE:RBLX), 리페어 테라퓨틱스(NASDAQ:RPTX) 및 케어DX(NASDAQ:CDNA)에 대해 큰 매매를 했다.

아크 인베스트: 유아이패스와 로블록스 주식을 계속 처분, 깃랩과 아이보타를 매수

ABSI

ACCD

ARKQ

ARKX

ESLT

ILMN

OKLO

화요일(21일) 캐시 우드가 이끄는 아크 인베스트는 애콜레이드(NASDAQ:ACCD), 디어(NYSE:DE), 인텔리아 테라퓨틱스(NASDAQ:NTLA), 유아이패스(NYSE:PATH), 카메코(NYSE:CCJ), 오클로(NYSE:OKLO), 일루미나(NASDAQ:ILMN), 엘빗 시스템즈(NASDAQ:ESLT), 앱사이(NASDAQ:ABSI)와 관련된 상당한 거래를 진행했다. 

아크 인베스트, 트럼프의 정책에 따라 방산주·에너지주 투자

Biotech

Health Care

Tech

CRSP

GOOGL

ORCL

구글 모기업 알파벳의 자회사인 스타트업 아이소모픽 랩스(Isomorphic Labs)는 올해 연말까지 최초의 인공지능(AI) 설계 의약품의 임상시험을 시작할 예정이다. 주요 기술 기업들이 AI 기반 의료 솔루션에 대한 투자를 늘리면서 제약 개발의 중요한 이정표가 될 것으로 보인다.

알파벳 자회사 아이소모픽 랩스, 올해 말까지 AI가 설계한 신약 임상시험 예정

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

JP Morgan analyst Philip Cusick maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Neutral and lowers the price target from $121 to $115.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Crown Castle, Lowers Price Target to $115

WIIM

AMTX

Aemetis shares are trading higher after Ascendiant Capital maintained a Buy rating on the stock and raised its price target from $18 to $19.

Jefferies analyst Lloyd Byrne maintains Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) with a Buy and lowers the price target from $73 to $48.

CIVI

Jefferies Maintains Buy on Civitas Resources, Lowers Price Target to $48

CRWD

CrowdStrike shares are trading higher. The stock may be moving higher after NTT DATA announced it expanded its partnership with the company to strengthen its cybersecurity services.

Keefe, Bruyette &amp; Woods analyst Tim Switzer reiterates Atlanticus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>) with a Market Perform and raises the price target from $45 to $52.

Reiteration

ATLC

Keefe, Bruyette & Woods Reiterates Market Perform on Atlanticus Holdings, Raises Price Target to $52

Hyperfine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares are <a href="https://www.benzinga.com/movers">surging on Monday</a>.
This medical device company company forged a <a href="https://www.benzinga.com/pressreleases/25/03/b44355476/hyperfine-and-nvidia-collaborate-to-revolutionize-neuroimaging-with-ai-powered-innovation">major partnership with NVIDIA Corp</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to advance its portable brain imaging technology.
By integrating NVIDIA&#8217;s AI knowledge and computing power with Hyperfine's Swoop system, the first FDA-approved AI-driven portable MRI, the collaboration seeks to make brain MRIs quicker, more intelligent, and more affordable worldwide, speeding up brain disease diagnosis.
The Swoop system tackles a critical challenge in health care, limited access to affordable and prompt brain imaging. More than three billion people globally are affected by brain diseases, including strokes and neurodegenerative disorders.
Through this collaboration, the two companies will focus on advancing AI-powered image reconstruction and integrating real-time clinical decision support into the Swoop system's workflow.
Also Read: <a href="https://www.benzinga.com/news/25/03/44355290/why-is-chinese-ev-charging-provider-naas-technologys-stock-surging-today">Why Is Chinese EV Charging Provider NaaS Technology&#8217;s Stock Surging Today?</a>
The goal is to enhance image quality, reduce scan times and enable quicker, more reliable diagnoses. By leveraging NVIDIA's suite of tools like NVIDIA DALI and MONAI, the Swoop system will continue to evolve, ultimately bringing faster, affordable brain MRIs to healthcare providers worldwide.
&#8220;Our mission is to make portable brain imaging faster, more intelligent, and increasingly accessible — ultimately improving health outcomes and reducing costs globally,&#8221; said President and CEO Maria Sainz.
&#8220;Partnering with NVIDIA presents an incredible opportunity to advance and accelerate our AI technology. I&#8217;m thrilled about the possibilities this collaboration brings for the future.&#8221;
Traditional MRI systems are often expensive and demand significant infrastructure, resulting in 90% of the world's population lacking timely diagnostic imaging.
Hyperfine&#8217;s portable, AI-driven MRI system offers an affordable and efficient alternative, enabling trained clinicians to perform imaging directly at the point of care.
HYPR Price Action: Hyperfine shares are trading higher by 27.31% at $1.17 at publication Monday.
Read Next: • <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44356299/why-is-clothing-firm-guess-stock-surging-today">Why Is Clothing Firm Guess Stock Surging Today?</a>

Photo: Shutterstock

Movers

Trading Ideas

General

HYPR

NVDA

Hyperfine, Nvidia Partner To Make Brain MRIs More Affordable

GRRR

Gorilla Technology Group shares are trading lower after Citron Research made comments criticizing the company on social media.

Deep-pocketed investors have adopted a bullish approach towards Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DELL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Dell Technologies. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $592,585, and 5 are calls, amounting to $727,725.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $145.0 for Dell Technologies during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Dell Technologies's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Dell Technologies's whale activity within a strike price range from $80.0 to $145.0 in the last 30 days. 
<h3>Dell Technologies Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742227253_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DELL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$7.5</td>
<td>$7.35</td>
<td>$7.35</td>
<td>$115.00</td>
<td>$551.2K</td>
<td>2.0K</td>
<td align="right">756</td>
</tr>
<tr>
<td>DELL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.45</td>
<td>$5.35</td>
<td>$5.35</td>
<td>$95.00</td>
<td>$510.3K</td>
<td>2.7K</td>
<td align="right">956</td>
</tr>
<tr>
<td>DELL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.75</td>
<td>$17.5</td>
<td>$17.8</td>
<td>$97.50</td>
<td>$67.6K</td>
<td>188</td>
<td align="right">40</td>
</tr>
<tr>
<td>DELL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.05</td>
<td>$6.8</td>
<td>$130.00</td>
<td>$44.2K</td>
<td>4.1K</td>
<td align="right">0</td>
</tr>
<tr>
<td>DELL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$48.55</td>
<td>$48.4</td>
<td>$48.55</td>
<td>$145.00</td>
<td>$43.6K</td>
<td>56</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h3>About Dell Technologies</h3>
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It is focused on premium and commercial personal computers and enterprise on-premises data center hardware. It holds top-three market shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners, and also relies heavily on channel partners to fulfill its sales.
Having examined the options trading patterns of Dell Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Dell Technologies</h3>
<ul>
<li>With a volume of 1,697,863, the price of DELL is up 2.85% at $98.4. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 73 days.</li>
</ul>
<h3>What Analysts Are Saying About Dell Technologies</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $138.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Dell Technologies, targeting a price of $116. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Dell Technologies with a target price of $150. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Dell Technologies with a target price of $145. 
&#x2A; An analyst from Loop Capital persists with their Buy rating on Dell Technologies, maintaining a target price of $130. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Dell Technologies, which currently sits at a price target of $150. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Dell Technologies, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

DELL

Behind the Scenes of Dell Technologies's Latest Options Trends

Investors with a lot of money to spend have taken a bearish stance on Oscar Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OSCR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 39 uncommon options trades for Oscar Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 7% bullish and 89%, bearish.
Out of all of the special options we uncovered, 35 are puts, for a total amount of $1,624,761, and 4 are calls, for a total amount of $257,420.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $15.0 for Oscar Health during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Oscar Health stands at 816.33, with a total volume reaching 173,385.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Oscar Health, situated within the strike price corridor from $10.0 to $15.0, throughout the last 30 days.
<h3>Oscar Health Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742227248_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.35</td>
<td>$2.3</td>
<td>$2.35</td>
<td>$15.00</td>
<td>$167.3K</td>
<td>1.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>OSCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.55</td>
<td>$2.4</td>
<td>$2.5</td>
<td>$15.00</td>
<td>$136.1K</td>
<td>1.5K</td>
<td>4.3K</td>
</tr>
<tr>
<td>OSCR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$10.00</td>
<td>$98.4K</td>
<td>54</td>
<td>260</td>
</tr>
<tr>
<td>OSCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.55</td>
<td>$1.95</td>
<td>$2.5</td>
<td>$15.00</td>
<td>$94.0K</td>
<td>1.5K</td>
<td>2.6K</td>
</tr>
<tr>
<td>OSCR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.0</td>
<td>$2.85</td>
<td>$3.0</td>
<td>$15.00</td>
<td>$90.0K</td>
<td>1.7K</td>
<td>501</td>
</tr>
</tbody>
</table>

<h3>About Oscar Health</h3>
Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.
<h3>Oscar Health's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,752,678, the OSCR's price is down by -2.04%, now at $12.95. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 50 days.</li>
</ul>
<h3>Expert Opinions on Oscar Health</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $16.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Wells Fargo downgraded its rating to Equal-Weight, setting a price target of $16. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Oscar Health with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

OSCR

Decoding Oscar Health's Options Activity: What's the Big Picture?

When your last name is Buffett, people assume your bank account reflects it. But for Nicole Buffett, the reality was far different. In a <a href="https://www.marieclaire.com/culture/news/a2342/warren-buffett-granddaughter-nicole-buffett/">2008 Marie Claire interview</a>, the granddaughter of billionaire investor Warren Buffett says she grew up with financial limits most wouldn't expect from one of the world's richest families.
Buffett, known for his frugality and deep belief in self-sufficiency, agreed to cover his grandchildren's college expenses—but nothing more. Nicole, an artist, attended a prestigious art school on her grandfather's dime. But when she needed a simple futon for her off-campus apartment, the answer was a firm no.
"You know what the rules are: school expenses only," she recalls being told by Buffett's secretary when she called his office for assistance.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>
<h2 class="wp-block-heading">Growing Up Buffett: A Name That Opens Doors—But Not Wallets</h2>
Nicole was just four years old when her mother married Warren Buffett's youngest son, Peter, who later adopted her and her twin sister. They were raised as part of the Buffett family, with Nicole making regular visits to her grandfather's Omaha home—an unassuming house <a href="https://www.benzinga.com/personal-finance/25/02/43612207/warren-buffett-has-lived-in-his-31500-home-for-67-years-and-calls-it-one-of-his-best-investments-but-warned-a-house-can-be-a-nightmare">he purchased in 1958 for $31,500</a>.
Despite Buffett's wealth, extravagance wasn't part of the family playbook. In the interview, Nicole talked about the small but memorable gifts, like the crisp $100 bill <a href="https://www.benzinga.com/personal-finance/24/12/42317960/warren-buffett-used-to-gift-loved-ones-10000-cash-for-christmas-but-switched-to-stocks-with-a-note-cash-them-in-or-hold-onto-them">Warren handed her one Christmas</a>. Family vacations were comfortable but far from opulent, and the Buffett philosophy was clear: merit, not money, would dictate success.
"I didn't even understand how wealthy my grandfather was until I was 17," Nicole admitted. She learned about his fortune when he landed on the cover of Forbes as the richest man in America. Her classmates bombarded her with questions, but at home, the message remained the same: "We'll be living our lives the same way and doing what we always do."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Buffett's philosophy on wealth was ironclad. He often spoke about the "ovarian lottery," emphasizing that being born into privilege shouldn't mean unlimited handouts. His children attended public schools, shared a family car, and were raised with the expectation that they would forge their own paths.
<h2 class="wp-block-heading">The Rift: From Buffett Granddaughter to Cut Off</h2>
While Nicole embraced the Buffett name, her connection to Warren came to a halt after she participated in "The One Percent," a documentary about wealth inequality. She spoke about her experience as part of one of the world's richest families—without her grandfather's permission.
In the film, she acknowledged that she had been fortunate to have her education covered but hinted at a desire for more involvement with the family fortune. "It would be nice to be involved with creating things for others with that money and to be involved in it. I feel completely excluded from it," she said while promoting the film on "<a href="https://www.oprah.com/oprahshow/class-in-america/all">Oprah</a>."
Her comments reportedly didn't sit well with Warren Buffett. Not long after, he made a point to clarify that, despite Peter's adoption, he did <a href="https://www.benzinga.com/personal-finance/24/09/40764691/i-have-not-emotionally-or-legally-adopted-you-warren-buffett-cut-off-his-granddaughter-and-she-c">not consider Nicole his granddaughter</a> "in a legal or emotional" sense.&nbsp;
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
<h2 class="wp-block-heading">A Name, but Not the Fortune</h2>
Back in 2008, Nicole had told Marie Claire she was making a living as an artist, earning around $40,000 per year—far from the billionaire lifestyle people would assume comes with her last name.&nbsp;
"It's easy for people to assume that the last name comes with unlimited access," she has said. "But that's never been the case for me."
For Warren Buffett, the rules have always been clear. College? Covered. Anything beyond that? You're on your own—even if all you need is a futon.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

Warren Buffett's Estranged Granddaughter Said He Paid For College—But When She Asked For A Futon, She Was Told 'You Know The Rules—School Only'

Deep-pocketed investors have adopted a bearish approach towards Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in XYZ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Block. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 31% leaning bullish and 56% bearish. Among these notable options, 3 are puts, totaling $174,424, and 13 are calls, amounting to $906,445.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $32.5 and $145.0 for Block, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Block's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Block's substantial trades, within a strike price spectrum from $32.5 to $145.0 over the preceding 30 days.
<h3>Block Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742227243_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XYZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$12.5</td>
<td>$9.8</td>
<td>$10.9</td>
<td>$77.50</td>
<td>$222.3K</td>
<td>26</td>
<td align="right">204</td>
</tr>
<tr>
<td>XYZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$32.0</td>
<td>$31.4</td>
<td>$31.4</td>
<td>$32.50</td>
<td>$163.2K</td>
<td>144</td>
<td align="right">138</td>
</tr>
<tr>
<td>XYZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.35</td>
<td>$6.95</td>
<td>$6.95</td>
<td>$97.50</td>
<td>$130.6K</td>
<td>41</td>
<td align="right">188</td>
</tr>
<tr>
<td>XYZ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$52.55</td>
<td>$51.25</td>
<td>$51.9</td>
<td>$110.00</td>
<td>$114.1K</td>
<td>0</td>
<td align="right">22</td>
</tr>
<tr>
<td>XYZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.0</td>
<td>$6.55</td>
<td>$6.55</td>
<td>$100.00</td>
<td>$49.1K</td>
<td>1.9K</td>
<td align="right">83</td>
</tr>
</tbody>
</table>

<h3>About Block</h3>
Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2024, Square's payment volume was almost USD 250 million.
In light of the recent options history for Block, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Block</h3>
<ul>
<li>With a volume of 2,640,969, the price of XYZ is up 1.8% at $58.25. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 45 days.</li>
</ul>
<h3>Professional Analyst Ratings for Block</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $98.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Block, which currently sits at a price target of $90. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $90. 
&#x2A; An analyst from Seaport Global has decided to maintain their Buy rating on Block, which currently sits at a price target of $101. 
&#x2A; An analyst from Macquarie persists with their Outperform rating on Block, maintaining a target price of $110. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Block, targeting a price of $100. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Block with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Decoding Block's Options Activity: What's the Big Picture?

Blackstone shares are trading higher after UBS upgraded the stock from Neutral to Buy.

Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) has outperformed the market over the past 5 years by 55.98% on an annualized basis producing an average annual return of 75.72%. Currently, Ovintiv has a market capitalization of $10.57 billion. 
Buying $1000 In OVV: If an investor had bought $1000 of OVV stock 5 years ago, it would be worth $14,985.45 today based on a price of $40.59 for OVV at the time of writing.
<h3>Ovintiv's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742227234_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Ovintiv 5 Years Ago Would Be Worth Today

Investors have reacted poorly to President Donald Trump&#8216;s tariff plans as markets <a href="https://www.benzinga.com/federal-reserve/25/02/43478246/market-inflation-bets-soar-as-10-year-breakeven-rate-hits-16-month-peak-it-will-slow-federal-reserve-policy-rate-cuts">price in inflation</a> and the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) briefly <a href="https://www.benzinga.com/government/regulations/25/03/44317410/sp-500-enters-technical-correction-as-trade-war-fears-rattle-markets">entered correction territory</a> on March 13.
National Economic Council Director Kevin Hassett defended Trump&#8217;s tariff decisions in an <a href="https://www.youtube.com/watch?v=9sgYuLM-lYg&amp;ab_channel=CNBCTelevision">appearance</a> on CNBC Monday morning.
&#8220;If you run it out over 10 years, the amount of tariff revenue that we&#8217;ve already collected&#8230; adds up to about a trillion dollars over 10 years, a trillion dollars we could use to give everyone a tax cut or reduce the deficit,&#8221; Hassett said.
Tariffs are taxes paid by American importers that are often passed along to consumers through price hikes. Opponents of Trump&#8217;s tariffs say his plans are inflationary and have already damaged financial markets. Although some countries, such as Canada, <a href="https://www.benzinga.com/news/25/03/44281882/canada-retaliates-with-20b-in-tariffs-on-us-goods-amid-trade-war">have responded negatively</a> to Trump&#8217;s tariffs, Hassett expects others to change their policies.
&#8220;Our expectation is there will be a lot of countries that do respond favorably to President Trump&#8217;s negotiations. President Trump is very flexible, he says that over and over, but my guess is there&#8217;s going to be a lot of countries that don&#8217;t&#8230; the countries that don&#8217;t are going to have to pay the tariffs,&#8221; Hassett said.
Economists and experts are largely opposed to Hassett&#8217;s insinuations to <a href="https://www.benzinga.com/news/econ-s/25/03/44205662/president-trump-wants-to-replace-income-tax-with-tariffs-national-economic-council-director-kevin-hassett-says">replace income taxes with tariffs</a>, citing tariffs&#8217; regressive nature that will leave low-income Americans paying more for goods.
Hassett says that between now and April 2, when Trump plans to implement reciprocal tariffs on other countries, &#8220;there will be some uncertainty&#8221; but thinks markets will see that Trump&#8217;s plans &#8220;make a great deal of sense.&#8221;
Also Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44357674/restaurant-sales-sink-recession-warning-or-just-weather-driven-dip">Restaurant Sales Sink: Recession Warning Or Just Weather-Driven Dip?</a></li>
</ul>
Photo: Shutterstock

Government

Politics

Economics

Hassett Acknowledges Tariff 'Uncertainty,' Says Trump's Plans Will 'Make A Great Deal Of Sense'

HOOD

Robinhood Markets shares are trading higher. The company announced it launched a prediction markets hub for customers to trade on the outcomes of world events.

TSLA

Tesla shares are trading lower after Mizuho cut its price target on the stock from $515 to $430. Additionally, reports of declining sales in various regions and protests outside of facilities may be weighing negatively on the stock.

On Monday, Protalix BioTherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLX#NASDAQ">PLX</a>)&nbsp;reported fiscal 2024 earnings of 4 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 1 cent</a>.
The company recorded 2024 sales of $53.40 million, up 31% year over year, slightly below the consensus of $53.94 million.
The increase resulted primarily from an increase of&nbsp;$11.8 million&nbsp;in sales to Chiesi, an increase of&nbsp;$0.6 million&nbsp;in sales to&nbsp;Brazil, and an increase of&nbsp;$0.1&nbsp;million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44352673/protalix-biotherapeutics-reports-fiscal-year-2024-financial-and-business-results" rel="noreferrer noopener">in sales to Pfizer</a>.
Protalix is a biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins expressed through its plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration approval of a protein produced through plant cell-based in suspension expression system.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-stock-falls" target="_blank" rel="noreferrer noopener">Incyte&#8217;s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls</a>
Protalix has licensed to Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix&#8217;s first product manufactured through ProCellEx, excluding in&nbsp;Brazil, where Protalix retains full rights. The FDA and the European Medicines Agency approved Protalix&#8217;s second product, Elfabrio, in&nbsp;May 2023.
&#8220;2024 was a record year in revenues from selling goods for Protalix, as we experienced increases in all three of our revenue streams, Chiesi, Pfizer, and Brazil,&#8221; said Dror Bashan, Protalix&#8217;s <a href="https://www.benzinga.com/pressreleases/25/03/n44352673/protalix-biotherapeutics-reports-fiscal-year-2024-financial-and-business-results" target="_blank" rel="noreferrer noopener">president and CEO</a>.
&#8220;We are pleased with the promising results from our first-in-human study of our gout candidate, PRX-115, in adult volunteers with elevated uric acid levels, and hope to build on this momentum with the goal of initiating a phase II clinical trial in patients with gout during the second half of 2025,&#8221; Bashan said. &#8220;At the same time, we continued to evaluate additional pipeline candidates, including PRX-119, for potential further development.&#8221; 
In&nbsp;September 2024, the company repaid its 7.50% Senior Secured Convertible Promissory Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.
&#8220;Now that our debt is fully repaid and we no longer have outstanding warrants, our balance sheet is stronger and we are well-positioned to continue executing on our strategy through 2025 and beyond,&#8221; Bashan added.
In December, Chiesi and Protalix BioTherapeutics announced that the European Medicines Agency validated the Variation Submission for pegunigalsidase alfa to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease. The currently approved dose of pegunigalsidase alfa is 1 mg/kg administered <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42385554/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-variation-submissi" rel="noreferrer noopener">every two weeks</a>.
Price Action: PLX stock is up 17.4% at $2.630 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44353774/eventful-monday-for-astrazeneca-aces-phase-3-hypoparathyroidism-trial-inks-technology-pact-european-approval-for-imfinzi-for-lung-cancer" target="_blank" rel="noreferrer noopener">Eventful Monday For AstraZeneca &#8211; What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock

Earnings

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Emeren Group shares are trading higher after Shah Parties submitted a non-binding proposal to acquire all outstanding shares not already owned for $2.00 per share.

Shares of Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) have been under pressure since the fourth-quarter earnings release on Feb. 26.
JPMorgan analysts blamed the persistent underperformance of BetterHelp and "a more challenging operating backdrop complicated by renewed macroeconomic concerns.&#8221;
The Teladoc Health Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beea6/lisa-gill">Analyst Lisa Gill</a> reaffirmed a Neutral rating, while reducing the price target from $13 to $11.
The Teladoc Health Thesis: The company is likely to generate Q1 revenues of $617.5 million, versus consensus of $619 million.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The adjusted EBITDA is likely to be $52.8 million, versus consensus of $53 million, she added.
The analyst projected full-year revenue estimate at $2.52 billion. That&#8217;s slightly higher than the consensus of $2,519 million.
The analyst also has a 2026 estimate of $2.56 billion, versus consensus of $2.558 billion.
Gill lowered the <a>adjusted EBITDA estimates for 2025 and 2026 from $311 million to $294 million and from $333 million to $314 million</a>, respectively.
"Our revenue estimates assume Integrated Care growth of +2% and +3% and we model BetterHelp down -7.7% and flat in FY25 and FY26, respectively," she wrote.
While the scale of Teladoc Health platform and the longer-term strategic direction are good, "there is more work to be done," Gill added.
Price Action: Shares of Teladoc Health had risen by 0.06% to $8.62 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43949618/cisco-and-nvidia-expand-ai-partnership-secure-us-government-authorization-for-cloud-security">Teladoc Health Partners With Eli Liily&#8217;s LillyDirect to Expand Access to Zepbound For Weight Loss</a></li>
</ul>
Photo courtesy of Teladoc
&nbsp;&nbsp;

Analyst Color

TDOC

Teladoc Health Q1 Preview: Analyst Says Strategic Direction Is Good, But There's 'More Work To Be Done'

U.S.-listed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) exchange-traded funds are grappling with their most <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44336034/new-etf-targets-convertible-bonds-of-bitcoin-holding-companies-like-strategy">prolonged stretch of net outflows</a> since their debut in January last year, as investors react to market volatility spurred by President Donald Trump's <a href="https://www.benzinga.com/media/25/03/44349466/trump-trade-policy-a-big-headache-for-customers-says-apple-supplier-foxconns-ceo-very-very-hard-to-predict-how-things-will-develop">tariff-driven trade policies</a>.
What Happened: Over the past five weeks, the group of 12 Bitcoin ETFs has collectively shed more than $5.5 billion, according to <a href="https://www.bloomberg.com/news/articles/2025-03-17/us-bitcoin-etfs-shed-5-5-billion-in-longest-run-of-outflows?embedded-checkout=true">data </a>compiled by Bloomberg.
The outflows, the longest since the funds launched, began shortly after Trump returned to the White House, illustrating that investor caution over trade tensions is currently outweighing the administration's <a href="https://www.benzinga.com/25/03/44301987/trumps-bitcoin-effect-up-50-in-first-terms-first-100-days-but-down-22-in-second-term-so-farwhats-next">crypto-friendly stance</a>.
"Bitcoin and crypto overall remain driven by the macro picture right now," said Greg Magadini, director of derivatives at Amberdata, in a note. "I don't expect Bitcoin to diverge from risk-assets for the time being."
Since hitting record highs following Trump's re-election in November, Bitcoin has faced mounting pressure, falling around 12% year-to-date. As of Friday morning in London, the digital asset was trading near $83,500.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44335772/morpheus-to-host-first-decentralized-ai-agents-builder-conference-in-austin">Morpheus To Host First Decentralized AI Agents Builder Conference In Austin</a>
Why It Matters: However, some market watchers believe the worst may be over for ETF redemptions.
Georgii Verbitskii, founder of crypto trading platform TYMIO, told Benzinga that ETF selling pressure has noticeably eased.
"Bitcoin ETF outflow is subsiding: Friday's sell-off was significantly lower in comparison to higher selling volumes observed in late February and early March," Verbitskii said. 
He noted that recent withdrawals likely reflect short-term volatility rather than a broader exit trend. 
"The market is currently in a brittle balance, and the situation with ETFs could turn positive closer to the weekend if Nasdaq stabilizes and the VIX gets back to normal."
Verbitskii added that the fading negative momentum in ETFs could set the stage for a recovery, should market conditions improve. 
For now, however, global risk aversion—sparked by trade tensions and wider macroeconomic uncertainty—continues to weigh on crypto assets alongside traditional equities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44335357/donald-trumps-official-meme-coin-worth-14-5-billion-on-inauguration-day-is-down-to-2-3-billion">Donald Trump&#8217;s Official Meme Coin, Worth $14.5 Billion On Inauguration Day, Is Down To $2.3 Billion</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin ETFs See Record $5.5 Billion In Outflows In 5 Weeks As Tariff Turbulence Looms

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

Legal

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. (NTLA) Shareholders

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

Small Cap

NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

Comments

Intellia Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌